(Press-News.org) LOS ANGELES — Approximately 7% of Americans have had long COVID, a range of ongoing health problems experienced after infection and recovery from COVID-19. Symptoms can include fatigue, brain fog, headaches, chest pain, heart palpitations and more.
To date, there is no proven treatment for the syndrome, and the mechanisms that cause it are not fully understood.
Now, a new clinical trial from Keck Medicine of USC is investigating if a diet designed to lower inflammation may play a role in easing this often debilitating condition.
The premise of the trial revolves around recent research indicating that long COVID may be caused by a hyper inflammatory response that becomes activated during COVID-19 as the body fights off the virus but, in some people, does not recede even after the infection has passed. High inflammation levels in the body can lead to organ damage and other health problems.
“We are examining if food choice can quiet the body’s inflammatory response and in doing so, effectively minimize or curtail long COVID symptoms,” said Adupa Rao, MD, an investigator of the clinical trial and medical director of the Keck Medicine Covid Recovery Clinic.
The study will examine the anti-inflammatory effect of a low-carbohydrate diet to lower blood glucose (sugar) levels in combination with a medical food that raises blood ketone levels. Ketones, including beta-hydroxybutyrate, the active ketone in this food, are chemicals the body produces to provide energy when the body is low on carbohydrates and sugars. A low-carb diet and ketones have both been associated with reduced inflammation in the body.
Researchers plan to enroll 50 long COVID patients being treated by Keck Medicine’s Covid Recovery Clinic. Half the individuals will receive a 30-day dietary intervention and half will not. At the end of the month, researchers will determine how patients tolerated the regimen as well as compare inflammatory markers and long COVID symptoms between the two groups of patients.
If the nutritional intervention is tolerated well by patients and improves their health issues, researchers plan to expand the clinical trial to a larger population.
"Research like ours is vital to expand our understanding of long COVID and ultimately help identify effective treatments to improve patients’ quality of life,” said principal investigator of the clinical trial, Nuria Pastor-Soler, MD, PhD, who is also an associate professor of medicine at the Keck School of Medicine of USC. “The results of this trial will hopefully move us closer to potential solutions.”
Ken Hallows, MD, PhD, a professor of medicine at the Keck School of Medicine, is also a researcher in this study. The clinical trial is funded by the Amy P. Goldman Foundation.
To learn more about the Keck Medicine Covid Recovery Clinic, please email covidrecovery@med.usc.edu or call 323-442-9209.
###
For more information about Keck Medicine of USC, please visit news.KeckMedicine.org.
END
Could a specialized diet alleviate long COVID?
Keck Medicine of USC launches clinical trial to investigate if a nutritional intervention designed to reduce inflammation could curb the condition that so far has no cure
2023-10-09
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Miriam Merad, M.D., Ph.D., elected to the National Academy of Medicine for seminal work in immunology and cell biology
2023-10-09
Miriam Merad, M.D., Ph.D., an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM) in recognition of her pioneering contributions to the fields of immunology and cell biology.
Dr. Merad was elected for her transformational discoveries, establishing for the first time that tissue-resident macrophages have distinct origins, maintain their lineage separately from adult hematopoiesis, and possess unique functions that enhance tissue health, repair, infection defense, and impact tumor outcomes.
She is the Mount Sinai Professor ...
New drug offers relief for treatment-resistant epilepsy patients
2023-10-09
In cases where standard therapies fail, a medication called XEN1101 reduces seizure frequency by more than 50% in some patients and sometimes eliminates them altogether, a new study shows. Unlike several treatments that must be started at low doses and slowly ramped up, the new drug can safety be taken at its most effective dose from the start, the authors say.
Focal seizures, the most common type seen in epilepsy, occur when nerve cells in a particular brain region send out a sudden, excessive burst of electrical signals. Along with seizures, this uncontrolled activity can lead to abnormal behavior, periods of lost awareness, and mood changes. ...
Capturing immunotherapy response in a blood drop
2023-10-09
*EMBARGOED UNTIL 11 A.M. MONDAY, OCT. 9*
Liquid biopsies are blood tests that can serially measure circulating tumor DNA (cell-free DNA that is shed into the bloodstream by dying cancer cells). When used in patients with advanced non-small cell lung cancer undergoing immunotherapy, they may identify patients who could benefit from treatment with additional drugs, according to a phase 2 clinical trial in the U.S. and Canada. The trial is led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel ...
Soccer goalies process the world differently, muti-sensory integration tests show
2023-10-09
In the game of soccer (association football), goalkeepers have a unique role. To do the job well, they must be ready to make split-second decisions based on incomplete information to stop their opponents from scoring a goal. Now researchers reporting in Current Biology on October 9 have some of the first solid scientific evidence that goalkeepers show fundamental differences in the way they perceive the world and process multi-sensory information.
“Unlike other football players, goalkeepers are required to make thousands of very fast decisions based on limited or incomplete sensory information,” says Michael Quinn, the study’s ...
Depressive symptoms and mortality among adults
2023-10-09
About The Study: This study of 23,000 individuals found a higher risk of all-cause, cardiovascular disease, and ischemic heart disease mortality among adults with moderate to severe depressive symptoms compared to those without depressive symptoms. Public health efforts to improve awareness and treatment of depression and associated risk factors could support a comprehensive, nationwide strategy to reduce the burden of depression.
Authors: Zefeng Zhang, M.D., Ph.D., of the Centers for Disease Control and Prevention in Atlanta, is the corresponding author.
To access the embargoed study: ...
Estimates of major depressive disorder and treatment among adolescents by race and ethnicity
2023-10-09
About The Study: During the first full calendar year of the pandemic, approximately 1 in 5 adolescents had major depressive disorder, and less than half of adolescents who needed treatment had any mental health treatment, according to this analysis of nationally representative survey data of 10,000 U.S. adolescents. Adolescents in racial and ethnic minority groups, particularly Latinx, experienced the lowest treatment rates.
Authors: Michael William Flores, Ph.D., M.P.H., of the Cambridge Health Alliance in Cambridge, Massachusetts, is the corresponding author.
To access ...
Cancer drug restores immune system’s ability to fight tumors
2023-10-09
A new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The University of Texas at Austin has found. In mouse models of melanoma, bladder cancer, leukemia and colon cancer, the drug slows the growth of tumors, extends lifespan and boosts the efficacy of immunotherapy. The research is published in the journal Cancer Cell and could be a game changer for many cancer patients.
Many cancers delete a stretch of DNA called 9p21, which is the most common deletion across all cancers, occurring in 25%-50% of certain cancers such as melanoma, bladder ...
Newfound mechanism suggests drug combination could starve pancreatic cancer
2023-10-09
A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
Led by researchers at NYU Grossman School of Medicine, its Department of Radiation Oncology, and the Perlmutter Cancer Center, the work builds on prior discoveries at NYU Langone that revealed how pancreatic cancer cells, to avert starvation and keep growing, find alternate fuel sources. Normally supplied by the bloodstream, oxygen, blood sugar, and other resources become scarce as the increasing density of fast-growing pancreatic tumors cuts off their own blood supply. ...
Epigenetic regulator MOF drives mitochondrial metabolism
2023-10-09
The intricate control of cellular metabolism relies on the coordinated and harmonious interplay between the nucleus and mitochondria. On the one hand, mitochondria are the hub for the production of essential metabolites, which aside from being required to meet the energy demands of the cell, also serve as the building blocks for constructing both genetic and epigenetic landscapes in the nucleus. On the other hand, the majority of mitochondrial metabolic enzymes are encoded by the nuclear genome, making the function of these two organelles highly interdependent on one another. Inter-organellar communication is aided by molecules that shuttle between these two compartments. ...
Do you know a stroke hero?
2023-10-09
Each year, approximately 800,000 people in the U.S. experience a stroke, according to the American Heart Association’s 2023 Heart Disease and Stroke Statistical Update. Individuals and groups making a difference in the stroke community have a chance to be nationally recognized with a 2024 Stroke Hero Award from the American Stroke Association, a division of the American Heart Association, which is devoted to a world of healthier lives for all.
Stroke is the fifth leading cause of death and a leading cause of serious, long-term ...
LAST 30 PRESS RELEASES:
University of Cincinnati experts present research at annual hematology event
ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial
ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer
ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors
Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient
Continuous and fixed-duration treatments result in similar outcomes for CLL
Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia
Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease
Roughly one-third of families with children being treated for leukemia struggle to pay living expenses
Quality improvement project results in increased screening and treatment for iron deficiency in pregnancy
IV iron improves survival, increases hemoglobin in hospitalized patients with iron-deficiency anemia and an acute infection
Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients
Emergency departments fall short on delivering timely treatment for sickle cell pain
Study shows no clear evidence of harm from hydroxyurea use during pregnancy
Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease
Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia
Early results suggest exa-cel gene therapy works well in children
NTIDE: Disability employment holds steady after data hiatus
Social lives of viruses affect antiviral resistance
Dose of psilocybin, dash of rabies point to treatment for depression
Helping health care providers navigate social, political, and legal barriers to patient care
Barrow Neurological Institute, University of Calgary study urges “major change” to migraine treatment in Emergency Departments
Using smartphones to improve disaster search and rescue
Robust new photocatalyst paves the way for cleaner hydrogen peroxide production and greener chemical manufacturing
Ultrafast material captures toxic PFAS at record speed and capacity
Plant phenolic acids supercharge old antibiotics against multidrug resistant E. coli
UNC-Chapel Hill study shows AI can dramatically speed up digitizing natural history collections
OYE Therapeutics closes $5M convertible note round, advancing toward clinical development
Membrane ‘neighborhood’ helps transporter protein regulate cell signaling
Naval aviator turned NPS doctoral student earns national recognition for applied quantum research
[Press-News.org] Could a specialized diet alleviate long COVID?Keck Medicine of USC launches clinical trial to investigate if a nutritional intervention designed to reduce inflammation could curb the condition that so far has no cure